Schroder Investment Management Group Has $3.44 Million Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Schroder Investment Management Group lessened its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 47.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,047 shares of the biopharmaceutical company's stock after selling 9,795 shares during the quarter. Schroder Investment Management Group owned 0.05% of Madrigal Pharmaceuticals worth $3,442,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Madrigal Pharmaceuticals during the fourth quarter worth about $70,000. KBC Group NV raised its holdings in Madrigal Pharmaceuticals by 73.5% in the fourth quarter. KBC Group NV now owns 609 shares of the biopharmaceutical company's stock valued at $188,000 after acquiring an additional 258 shares in the last quarter. Miracle Mile Advisors LLC acquired a new stake in Madrigal Pharmaceuticals in the fourth quarter valued at approximately $216,000. D.A. Davidson & CO. acquired a new stake in Madrigal Pharmaceuticals in the fourth quarter valued at approximately $221,000. Finally, Atria Investments Inc acquired a new stake in Madrigal Pharmaceuticals in the fourth quarter valued at approximately $222,000. Hedge funds and other institutional investors own 98.50% of the company's stock.

Insider Buying and Selling at Madrigal Pharmaceuticals

In other news, CEO William John Sibold sold 1,584 shares of the firm's stock in a transaction on Friday, January 24th. The stock was sold at an average price of $335.24, for a total transaction of $531,020.16. Following the transaction, the chief executive officer now directly owns 54,303 shares of the company's stock, valued at approximately $18,204,537.72. This trade represents a 2.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Rebecca Taub sold 1,689 shares of the stock in a transaction on Friday, January 17th. The shares were sold at an average price of $273.41, for a total value of $461,789.49. Following the completion of the transaction, the chief marketing officer now owns 457,310 shares of the company's stock, valued at $125,033,127.10. This trade represents a 0.37 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 35,900 shares of company stock worth $12,168,079 in the last 90 days. 22.80% of the stock is owned by company insiders.

Remove Ads

Analysts Set New Price Targets

MDGL has been the topic of several recent analyst reports. HC Wainwright increased their price target on shares of Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. JMP Securities reiterated a "market outperform" rating and issued a $427.00 price target on shares of Madrigal Pharmaceuticals in a research note on Friday, January 10th. Citigroup increased their price target on shares of Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. Finally, B. Riley upgraded shares of Madrigal Pharmaceuticals from a "hold" rating to a "strong-buy" rating and raised their target price for the stock from $236.00 to $422.00 in a research report on Thursday, February 27th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $378.44.

Madrigal Pharmaceuticals Price Performance

Madrigal Pharmaceuticals stock traded down $16.36 during midday trading on Thursday, reaching $297.60. The company's stock had a trading volume of 35,126 shares, compared to its average volume of 389,820. Madrigal Pharmaceuticals, Inc. has a fifty-two week low of $189.00 and a fifty-two week high of $377.46. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.93 and a current ratio of 5.98. The stock's 50 day simple moving average is $331.80 and its 200 day simple moving average is $302.45. The firm has a market capitalization of $6.57 billion, a PE ratio of -12.01 and a beta of -0.69.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.32) by $1.61. The firm had revenue of $103.32 million for the quarter, compared to analyst estimates of $97.81 million. On average, equities research analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current year.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.